tablet-yellow

Aprepitant (Aponvie, Emend)

Anesthesia Implications

Clinically reviewed by anesthesia providers · Updated

Classification:
Neurokinin-1 (NK1) receptor antagonist, antiemetic
Therapeutic Effects:
Antiemetic, substance P antagonism, PONV and chemotherapy-induced nausea and vomiting (CINV) prevention
Primary Considerations:

PONV prophylaxis - Single 32 mg IV over 2 min within 30 min before induction; the long half-life covers 24-48 h, useful for delayed PONV. Long duration - 9-13 h half-life gives superior 24-48 h...

Continue reading

Read the full drug post with a free account

Free. It opens every drug, surgery and condition in the library.

Already have an account?